Juvenile idiopathic arthritis: Classification, clinical presentation and current treatments

Hormone Research

Volumn 72, Issue SUPPL. 1, 2009, Pages 4-12

  Dannecker, Günther E ^a   Quartier, Pierre ^b  

^a OLGAHOSPITAL   (Germany)

^b UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

Classification; Juvenile idiopathic arthritis; Presentation; Treatment

Indexed keywords

ABATACEPT; ADALIMUMAB; ANTINUCLEAR ANTIBODY; CANAKINUMAB; CORTICOSTEROID; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; GROWTH HORMONE; HLA B27 ANTIGEN; IBUPROFEN; IMMUNOGLOBULIN M; INDOMETACIN; INFLIXIMAB; INTERLEUKIN 1 ANTIBODY; LEFLUNOMIDE; MELOXICAM; METHOTREXATE; METHYLPREDNISOLONE; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RHEUMATOID FACTOR; RILONACEPT; RITUXIMAB; SALAZOSULFAPYRIDINE; STEROID; TOCILIZUMAB; TRIAMCINOLONE HEXACETONIDE;

ABDOMINAL PAIN; ANKYLOSING SPONDYLITIS; ARTHRITIS; ARTICLE; ATROPHY; CHILD; CLINICAL FEATURE; DECREASED APPETITE; DISEASE CLASSIFICATION; DRUG BINDING; DRUG EFFICACY; DRUG HALF LIFE; DRUG WITHDRAWAL; ENTHESITIS RELATED ARTHRITIS; ERYTHROPHAGOCYTOSIS; FATIGUE; FEVER; GASTROINTESTINAL TOXICITY; GROWTH DISORDER; HORMONE SUBSTITUTION; HUMAN; HYPOPIGMENTATION; IRIDOCYCLITIS; JUVENILE RHEUMATOID ARTHRITIS; KNEE ARTHRITIS; LEG LENGTH INEQUALITY; LOW DRUG DOSE; MACROPHAGE ACTIVATION SYNDROME; MENTAL CONCENTRATION; MOOD CHANGE; MORNING STIFFNESS; MUSCLE ATROPHY; NAUSEA; PHYSIOTHERAPY; POLYARTHRITIS; PRIORITY JOURNAL; PSEUDOPORPHYRIA; PSORIASIS; PSORIATIC ARTHRITIS; PSYCHOSOCIAL CARE; RASH; RHEUMATIC FEVER; RHEUMATOID ARTHRITIS; SEX DIFFERENCE; SIDE EFFECT; SYSTEMIC ARTHRITIS; UNSPECIFIED SIDE EFFECT; UVEITIS; VOMITING;

ADOLESCENT; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, JUVENILE RHEUMATOID; CHILD; FEMALE; HUMANS; MALE; TUMOR NECROSIS FACTOR-ALPHA;

EID: 73649102432     PISSN: 03010163     EISSN: None     Source Type: Journal    
DOI: 10.1159/000229757     Document Type: Article

References (39)

1. Petty RE, Southwood TR, Manners P, Baum J, Glass DN, Goldenberg J, He X, Maldonado-Cocco J, Orozco-Alcala J, Prieur AM, Suarez-Almazor ME, Woo P: International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001. J Rheumatol 2004; 31: 390-392
2. Minden K: Epidemiologie; in Wagner N, Dannecker G (eds): Padiatrische Rheumatologie. Heidelberg, Springer Medizin Verlag, 2007, pp 179-181
3. Manners PJ, Bower C: Worldwide prevalence of juvenile arthritis why does it vary so much? J Rheumatol 2002; 29: 1520-1530
4. Oen KG, Cheang M: Epidemiology of chronic arthritis in childhood. Semin Arthritis Rheum 1996; 26: 575-591
5. Still G: On a form of chronic joint disease in children. Medico-Chirurgical Transactions 1897; 80: 47-59
6. de Benedetti F, Martini A: Targeting the interleukin-receptor: a new treatment for systemic juvenile idiopathic arthritis? Arthritis Rheum 2005; 52: 687-693
7. Pascual V, Allantaz F, Arce E, Punaro M, Banchereau J: Role of interleukin-1 (IL-1) in the pathogenesis of systemic onset juvenile idiopathic arthritis and clinical response to IL-1 blockade. J Exp Med 2005; 201: 1479-1486
8. Behrens EM, Beukelman T, Paessler M, Cron RQ: Occult macrophage activation syndrome in patients with systemic juvenile idiopathic arthritis. J Rheumatol 2007; 34: 1133-1138
9. Souza LS, Machado SH, Brenol CV, Brenol JC, Xavier RM: Growth velocity and interleukin concentrations in juvenile idiopathic arthritis. J Rheumatol 2008; 35: 2265-2271
10. Ravelli A, Felici E, Magni-Manzoni S, Pistorio A, Novarini C, Bozzola E, Viola S, Martini A: Patients with antinuclear antibody-positive juvenile idiopathic arthritis constitute a homogeneous subgroup irrespective of the course of joint disease. Arthritis Rheum 2005; 52: 826-832
11. Taurog JD: The mystery of HLA-B27: if it isn't one thing, it's another. Arthritis Rheum 2007; 56: 2478-2481
12. Ravelli A, Martini A: Juvenile idiopathic arthritis. Lancet 2007; 369: 767-778
13. Minden K, Niewerth M, Listing J, Biedermann T, Bollow M, Schontube M, Zink A: Long-term outcome in patients with juvenile idiopathic arthritis. Arthritis Rheum 2002; 46: 2392-2401
14. Giannini EH, Brewer EJ, Miller ML, Gibbas D, Passo MH, Hoyeraal HM, Bernstein B, Person DA, Fink CW, Sawyer LA, et al: Ibuprofen suspension in the treatment of juvenile rheumatoid arthritis. Pediatric Rheumatology Collaborative Study Group. J Pediatr 1990; 117: 645-652
15. Leak AM, Richter MR, Clemens LE, Hall MA, Ansell BM: A crossover study of naproxen, diclofenac and tolmetin in seronegative juvenile chronic arthritis. Clin Exp Rheumatol 1998; 6: 157-160
16. Schad SG, Kraus A, Haubitz I, Trcka J, Hamm H, Girschick HJ: Early onset pauciarticular arthritis is the major risk factor for naproxen-induced pseudoporphyria in juvenile idiopathic arthritis. Arthritis Res Ther 2007; 9: R10
17. Ruperto N, Nikishina I, Pachanov ED, Shachbazian Y, Prieur AM, Mouy R, Joos R, Zulian F, Schwarz R, Artamonova V, Emminger W, Bandeira M, Buoncompagni A, Foeldvari I, Falcini F, Baildam E, Kone-Paut I, Alessio M, Gerloni V, Lenhardt A, Martini A, Hanft G, Sigmund R, Simianer S: A randomized, double-blind clinical trial of two doses of meloxicam compared with naproxen in children with juvenile idiopathic arthritis: short-and long-term efficacy and safety results. Arthritis Rheum 2005; 52: 563-572
18. Eberhard BA, Sison MC, Gottlieb BS, Ilowite NT: Comparison of the intraarticular effectiveness of triamcinolone hexacetonide and triamcinolone acetonide in treatment of juvenile rheumatoid arthritis. J Rheumatol 2004; 31: 2507-2512
19. Breit W, Frosch M, Meyer U, Heinecke A, Ganser G: A subgroup-specific evaluation of the efficacy of intraarticular triamcinolone hexacetonide in juvenile chronic arthritis. J Rheumatol 2000; 27: 2696-2702
20. Padeh S, Passwell JH: Intraarticular corticosteroid injection in the management of children with chronic arthritis. Arthritis Rheum 1998; 41: 1210-1214
21. Zulian F, Martini G, Gobber D, Plebani M, Zacchello F, Manners P: Triamcinolone acetonide and hexacetonide intra-articular treatment of symmetrical joints in juvenile idiopathic arthritis: a double-blind trial. Rheumatology (Oxford) 2004; 43: 1288-1291
22. Sherry DD, Stein LD, Reed AM, Schanberg LE, Kredich DW: Prevention of leg length discrepancy in young children with pauciarticular juvenile rheumatoid arthritis by treatment with intraarticular steroids. Arthritis Rheum 1999; 42: 2330-2334
23. Giannini EH, Brewer EJ, Kuzmina N, Shaikov A, Maximov A, Vorontsov I, Fink CW, Newman AJ, Cassidy JT, Zemel LS: Methotrexate in resistant juvenile rheumatoid arthritis. Results of the U.S.A.-U.S.S.R. double-blind, placebo-controlled trial. The Pediatric Rheumatology Collaborative Study Group and The Cooperative Children's Study Group. N Engl J Med 1992; 326: 1043-1049
24. Ruperto N, Murray KJ, Gerloni V, Wulffraat N, de Oliveira SK, Falcini F, Dolezalova P, Alessio M, Burgos-Vargas R, Corona F, Vesely R, Foster H, Davidson J, Zulian F, Asplin L, Baildam E, Consuegra JG, Ozdogan H, Saurenmann R, Joos R, Pistorio A, Woo P, Martini A: A randomized trial of parenteral methotrexate comparing an intermediate dose with a higher dose in children with juvenile idiopathic arthritis who failed to respond to standard doses of methotrexate. Arthritis Rheum 2004; 50: 2191-2201
25. Alsufyani K, Ortiz-Alvarez O, Cabral DA, Tucker LB, Petty RE, Malleson PN: The role of subcutaneous administration of methotrexate in children with juvenile idiopathic arthritis who have failed oral methotrexate. J Rheumatol 2004; 31: 179-182
26. Van Rossum MA, van Soesbergen RM, Boers M, Zwinderman AH, Fiselier TJ, Franssen MJ, Ten Cate R, Van Suijlekom-Smit LW, Wulffraat NM, van Luijk WH, Oostveen JC, Kuis W, Dijkmans BA: Long-term outcome of juvenile idiopathic arthritis following a placebo controlled trial: sustained benefits of early sulfasalazine treatment. Ann Rheum Dis 2007; 66: 1518-1524
27. Silverman E, Mouy R, Spiegel L, Jung LK, Saurenmann RK, Lahdenne P, Horneff G, Calvo I, Szer IS, Simpson K, Stewart JA, Strand V, the Leflunomide in Juvenile Rheumatoid Arthritis (JRA) Investigator Group: leflunomide or methotrexate for juvenile rheumatoid arthritis. N Engl J Med 2005; 352: 1655-1666
28. Lovell DJ, Giannini EH, Reiff A, Cawkwell GD, Silverman ED, Nocton JJ, Stein LD, Gedalia A, Ilowite NT, Wallace CA, Whitmore J, Finck BK: Etanercept in children with polyarticular juvenile rheumatoid arthritis. Pediatric Rheumatology Collaborative Study Group. N Engl J Med 2000; 342: 763-769
29. Horneff G, Schmeling H, Biedermann T, Foeldvari I, Ganser G, Girschick HJ, Hospach T, Huppertz HI, Keitzer R, Kuster RM, Michels H, Moebius D, Rogalski B, Thon A: The German Etanercept Registry for treatment of juvenile idiopathic arthritis. Ann Rheum Dis 2004; 63: 1638-1644
30. Gerloni V, Pontikaki I, Gattinara M, Desiati F, Lupi E, Lurati A, Salmaso A, Fantini F: Efficacy of repeated intravenous infusions of an anti-tumor necrosis factor alpha monoclonal antibody, infliximab, in persistently active, refractory juvenile idiopathic arthritis: results of an open-label prospective study. Arthritis Rheum 2005; 52: 548-553
31. Lovell D, Ruperto N, Goodman S, Reiff A, Martini A, Giannini E, Radin A, Rao V, Spencer-Grenn G: Preliminary data from the study of adalimumab in children with juvenile idiopathic arthritis. Arthritis Rheum 2004; 50:S436
32. Lahdenne P, Vahasalo P, Honkanen V: Infliximab or etanercept in the treatment of children with refractory juvenile idiopathic arthritis: an open label study. Ann Rheum Dis 2003; 62: 245-247
33. Yokota S, Imagawa T, Mori M, Miyamae T, Aihara Y, Takei S, Iwata N, Umebayashi H, Murata T, Miyoshi M, Tomiita M, Nishimoto N, Kishimoto T: Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled, withdrawal phase III trial. Lancet 2008; 371: 998-1006
34. Ruperto N, Lovell DJ, Quartier P, Paz E, Rubio-Perez N, Silva CA, Abud-Mendoza C, Burgos-Vargas R, Gerloni V, Melo-Gomes JA, Saad-Magalhaes C, Sztajnbok F, Goldenstein-Schainberg C, Scheinberg M, Penades IC, Fischbach M, Orozco J, Hashkes PJ, Hom C, Jung L, Lepore L, Oliveira S, Wallace CA, Sigal LH, Block AJ, Covucci A, Martini A, Giannini EH; Paediatric Rheumatology International Trials Organization; Pediatric Rheumatology Collaborative Study Group: Abatacept in children with juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled withdrawal trial. Lancet 2008; 372: 383-391
35. El-Hallak M, Binstadt BA, Leichtner AM, Bennett CM, Neufeld EJ, Fuhlbrigge RC, Zurakowski D, Sundel RP: Clinical effects and safety of rituximab for treatment of refractory pediatric autoimmune diseases. J Pediatr 2007; 150: 376-382
36. Simon D, Prieur AM, Quartier P, Charles Ruiz J, Czernichow P: Early recombinant human growth hormone treatment in glucocorticoid-treated children with juvenile idiopathic arthritis: a 3-year randomized study. J Clin Endocrinol Metab 2007; 92: 2567-2573
37. Oen K, Malleson PN, Cabral DA, Rosenberg AM, Petty RE, Cheang M: Disease course and outcome of juvenile rheumatoid arthritis in a multicenter cohort. J Rheumatol 2002; 29: 1989-1999
38. Singh-Grewal D, Schneider R, Bayer N, Feldman BM: Predictors of disease course and remission in systemic juvenile idiopathic arthritis: significance of early clinical and laboratory features. Arthritis Rheum 2006; 54: 1595-1601
39. Lehman TJ, Schechter SJ, Sundel RP, Oliveira SK, Huttenlocher A, Onel KB: Thalidomide for severe systemic onset juvenile rheumatoid arthritis: a multicenter study. J Pediatr 2004; 145: 856-857